Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions

Prostate Cancer

Interventions

DRUG

PSMA-Targeted [In-111]-Labeled Trillium Compound

Radiotracer

DRUG

PTI-122

Cytoprotective agent

Trial Locations (4)

Advanced Molecular Imaging & Therapy, Glen Burnie

Biogenix Molecular, Miami

University of Tennessee Medical Center, Knoxville

XCancer Omaha/Urology Cancer Center, Omaha

All Listed Sponsors

lead

Ratio Therapeutics, Inc.

INDUSTRY